As Wall Street piled back into cannabis stocks on Friday, many in the insurance industry were asking a different question: if Washington moves ahead with a major softening of federal marijuana rules, is the long‑deferred boom in cannabis cover finally about to arrive?
Shares in major producers and funds surged after reports that President Donald Trump is expected to issue an executive order as soon as Monday directing federal agencies to reclassify marijuana. One person familiar with the plans told CNBC that the order would pave the way for the drug to be moved from tightly policed Schedule I status to the less restrictive Schedule III category under federal law, a shift that would bring it in line with “steroids and Tylenol with codeine.”
Tilray Brands and Canopy Growth jumped more than 40 per cent in New York trading. A specialist fund, the Amplify Seymour Cannabis ETF, rallied around 51 per cent, putting it on track for its best day on record. Yet even with Friday’s spike, the ETF is still heading for its fifth straight annual loss.
Behind the market swing lies an expectation that a regulatory door is about to open. Rescheduling “would be ‘positive’ for the cannabis industry, allowing banks to serve the sector,” wrote Ed Groshans of Compass Point, who had argued that “Trump rescheduling marijuana was not an if, in our assessment, but a when.”
For insurers, the prospect is no less significant.
Under current federal rules, marijuana sits in the same legal tier as heroin and LSD. That classification has left insurers threading a narrow path between state‑level legalisation and a federal prohibition that complicates everything from banking to reinsurance. Many large carriers have stayed out of the space entirely, worried that offering comprehensive cover to growers, processors and retailers could expose them to money‑laundering or racketeering allegations.
A move to Schedule III would not legalise cannabis outright, and it would not sweep away the patchwork of state laws. But it would lower the temperature of federal enforcement and remove some of the most acute barriers to doing business with regulated operators.
Trump “cannot unilaterally reclassify marijuana,” said Shane Pennington, a lawyer representing companies involved in litigation on the issue, but he can push the Justice Department to accelerate a final rule. Pennington called the proposed change “the biggest reform in federal cannabis policy since marijuana was made a Schedule I drug in the 1970s.”
If the administration follows through, carriers say they can begin to treat cannabis more like other heavily regulated but insurable sectors: pharmaceuticals, alcohol, and tobacco. That would not make underwriting simple. But it would shift the conversation from whether to insure at all to how to price and structure protection.
Specialty brokers and underwriters identify several lines that could see immediate interest if rescheduling goes ahead and mainstream capital follows.
Cannabis businesses have long struggled to secure robust protection for greenhouses, warehouses and retail premises, often depending on small surplus lines carriers charging steep premiums. As the industry matures and facilities scale up, demand for higher limits and more sophisticated business interruption cover – especially for energy‑intensive indoor grows – is likely to grow.
Indoor and outdoor cultivation exposes balance sheets to fire, equipment breakdown, weather, mould and theft. If federal rules relax and banking access improves, lenders will insist on broader crop and stock cover as a condition of finance. That, in turn, will require better data on yields, loss frequency and security controls than has been available to date.
Edible and vape products carry exposure ranging from mislabelling and contamination to alleged health impacts. Rescheduling would ease research restrictions, potentially clarifying some of the scientific uncertainty that has deterred underwriters. It would also make it easier to design structured recall and crisis‑management covers similar to those used in the food and beverage sector.
As valuations rebound and access to public markets improves, issuers are likely to seek more conventional D&O programmes. Underwriters would need to grapple with securities litigation risk, accounting practices in a volatile sector, and the possibility of policy challenges tied to any future regulatory reversals.
Law firms, accountants, consultants and technology vendors that specialise in cannabis have generally relied on bespoke E&O wording or exclusions‑carved policies. A clearer federal framework may support more standardised offerings, particularly if Congress eventually backs a comprehensive regime for licensing, safety and marketing.
From grow‑house labour to retail staff, expanding payrolls will bring more conventional comp and health exposures. At present, uncertainty around workplace safety protocols and impairment testing has been a sticking point in some states. Better research and more detailed regulation, proponents say, could make those risks easier to underwrite.
Much of the potential insurance upside hinges on the banking system. Groshans argued that rescheduling would encourage banks to serve the sector, reducing the reliance on cash and informal finance that has long plagued cannabis businesses.
If federally regulated lenders step in more confidently, insurers expect a knock‑on effect: loan covenants that standardise insurance requirements, greater transparency over financials, and a more reliable premium base. A sector that has sometimes resembled an informal cash economy would start to look more like a conventional, audited industry.
That shift would also matter for reinsurers, many of which have been wary of backing programmes where the ultimate legality of underlying activities remained contested. A Schedule III designation, even without full legalisation, could be enough for some to reconsider.
Executives inside the industry are talking about a turning point. “I’m a lot more optimistic than I ever have been,” Tilray chief executive Irwin Simon told CNBC. Shawn Hauser, a lawyer at Vicente LLP, called rescheduling a “partial victory” and “the beginning of a new era of public health policy,” while warning that advocates will still need to push for broader legal reforms.
For insurance leaders, the tone is more measured. Rescheduling, they note, is not the same as comprehensive legislative change. A White House official has already said that “no final decisions have been made on rescheduling of marijuana.” The Drug Enforcement Administration still must complete its process. A Supreme Court decision on the relationship between state regimes and federal prohibition could accelerate or complicate the timeline.
There is also a political question. Marijuana has become a multi‑billion‑dollar industry, with medical programmes in dozens of states and full recreational legalisation in nearly half. But the planned shift has already encountered scepticism from senior Republicans. House Speaker Mike Johnson laid out a list of objections in a recent call with the president, citing studies and data, according to people familiar with the discussion.
For now, carriers are running scenarios rather than rewriting appetites. Some are quietly revisiting exclusionary language and wordings in anticipation of change. Others are talking with brokers about how to collect better data on loss experience, particularly in property and liability lines, so that pricing does not lag behind reality if demand spikes.
Insurers are also weighing reputational concerns. Even if federal rules ease, some boards remain wary of being seen as early movers into a business that still divides voters and is associated, in the minds of some customers, with broader debates over addiction and public health.
The history of cannabis investing is a reminder of how quickly enthusiasm can outrun fundamentals. Tilray’s share price, now near $10, once traded above $2,000 on a split‑adjusted basis. The Amplify cannabis fund, despite Friday’s surge, is still set to post another annual loss.
Insurance executives say they are determined not to repeat that pattern. The likely trajectory, they argue, is not a sudden flood of capacity but a gradual expansion, led by specialty carriers and MGAs that already operate at the edges of the market. Only if rescheduling is followed by consistent enforcement, clearer banking rules and perhaps congressional action would a truly mainstream insurance market emerge.
Still, even cautious underwriters see a structural shift in the making. After “nearly a century of outdated drug policies,” as Hauser put it, an asset class that has existed in a regulatory grey zone may be inching toward the kind of legal status that actuaries, compliance officers and reinsurers know how to handle.
If the White House follows through, and if the rule survives legal and political challenge, cannabis businesses may finally find that the hardest cover to buy – comprehensive, competitively priced insurance from household‑name carriers – starts to come within reach. Whether that becomes a boom or merely a steady new line of business will depend not just on politics in Washington, but on how quickly the industry can prove to sceptical insurers that it is a risk worth taking.
